You are using an older browser version. Please use a supported version for the best MSN experience.

ZOSANO PHARMA CORPORATION

NASDAQ: ZSAN
1.56
+0.20
+14.71%

Sector

Healthcare

Industry

Biotechnology & Medical Research

Zosano Pharma Corporation is a clinical-stage biopharmaceutical company. The Company is focused on providing systemic administration of therapeutics to patients using its Adhesive Dermally-Applied Microarray (ADAM) technology. ADAM is an intracutaneous delivery system designed to offer drug absorption into the bloodstream. ADAM consists of an array of drug-coated titanium microneedles mounted on an adhesive backing that is pressed on to the skin using a reusable handheld applicator. The Company’s Qtrypta (M207) is a formulation of zolmitriptan delivered utilizing its ADAM technology. Qtrypta (M207) is being investigated as a treatment to provide relief of migraine symptoms in the migraine cycle. The Company has developed its transdermal delivery system to administer novel formulations of existing drugs through the skin for the treatment of a variety of indications.

Key People

John P. Walker

Chairman of the Board

Eric Scharin

Vice President - Technical Operations

Thorsten von Stein

Chief Medical Officer

Joseph Patrick Hagan

Director

Steven A. Elms

Independent Director

  • Zosano Pharma Corp

  • 34790 Ardentech Ct

  • FREMONT, CA 94555-3657

  • US.Map

  • Phone: +1 510 7451200

  • Fax: +1 302 6555049

  • zosanopharma.com

Incorporated

2012

Employees

56

Insider Trades
  • Recent
  • All
  • Date

  • Name

  • Transaction

  • Shares

  • Price(s)

  • Value

    • 6/25/2020

    • GREATHOUSE KENNETH R

    • Grant

    • 7,500

    • NA

    • NA

    • 6/25/2020

    • KELLERMAN DONALD J

    • Grant

    • 18,750

    • NA

    • NA

    • 6/25/2020

    • GRAIS LINDA S

    • Grant

    • 7,500

    • NA

    • NA

    • 6/25/2020

    • ELMS STEVEN A

    • Grant

    • 7,500

    • NA

    • NA

    • 6/25/2020

    • WALKER JOHN PETER

    • Grant

    • 7,500

    • NA

    • NA

    • 6/25/2020

    • XANTHOPOULOS KLEANTHIS G

    • Grant

    • 7,500

    • NA

    • NA

    • 6/25/2020

    • HAGAN JOSEPH P

    • Grant

    • 7,500

    • NA

    • NA

    • 6/25/2020

    • LO STEVEN

    • Grant

    • 146,250

    • NA

    • NA

    • 6/25/2020

    • LEWIS (HAYLEY)

    • Grant

    • 18,750

    • NA

    • NA

    • 6/25/2020

    • MATTHEWS CHRISTINE E

    • Grant

    • 18,750

    • NA

    • NA

    • 12/2/2019

    • AISLING CAPITAL IV, L.P.

    • Grant

    • 689,655

    • 1.45

    • 999,999.75

    • Date

    • Name

    • Transaction

    • Shares

    • Price(s)

    • Value

      • 6/25/2020

      • GREATHOUSE KENNETH R

      • Grant

      • 7,500

      • NA

      • NA

      • 6/25/2020

      • KELLERMAN DONALD J

      • Grant

      • 18,750

      • NA

      • NA

      • 6/25/2020

      • GRAIS LINDA S

      • Grant

      • 7,500

      • NA

      • NA

      • 6/25/2020

      • ELMS STEVEN A

      • Grant

      • 7,500

      • NA

      • NA

      • 6/25/2020

      • WALKER JOHN PETER

      • Grant

      • 7,500

      • NA

      • NA

      • 6/25/2020

      • XANTHOPOULOS KLEANTHIS G

      • Grant

      • 7,500

      • NA

      • NA

      • 6/25/2020

      • HAGAN JOSEPH P

      • Grant

      • 7,500

      • NA

      • NA

      • 6/25/2020

      • LO STEVEN

      • Grant

      • 146,250

      • NA

      • NA

      • 6/25/2020

      • LEWIS (HAYLEY)

      • Grant

      • 18,750

      • NA

      • NA

      • 6/25/2020

      • MATTHEWS CHRISTINE E

      • Grant

      • 18,750

      • NA

      • NA

      • 12/2/2019

      • AISLING CAPITAL IV, L.P.

      • Grant

      • 689,655

      • 1.45

      • 999,999.75

      AdChoices
      AdChoices
      AdChoices
      image beaconimage beaconimage beacon